222 related articles for article (PubMed ID: 37065335)
1. Breakthrough Hemolysis Associated With COVID-19 Vaccination and Active COVID-19 Infection in a Patient With Paroxysmal Nocturnal Hemoglobinuria Maintained on Pegcetacoplan: A Case Report.
Boshkos MC; Fives KR; Phrathep DD; Healey KD; Patel M
Cureus; 2023 Mar; 15(3):e36240. PubMed ID: 37065335
[TBL] [Abstract][Full Text] [Related]
2. Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH.
Griffin M; Kelly RJ; Panse J; de Castro C; Szer J; Horneff R; Tan L; Yeh M; Peffault de Latour R
Blood Adv; 2024 Apr; 8(7):1776-1786. PubMed ID: 38315872
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
Wong RSM
Ther Adv Hematol; 2022; 13():20406207221114673. PubMed ID: 35923770
[TBL] [Abstract][Full Text] [Related]
5. Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan.
Fattizzo B; Versino F; Zaninoni A; Marcello APML; Vercellati C; Artuso S; Barcellini W
Front Immunol; 2022; 13():1060923. PubMed ID: 36532073
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
[TBL] [Abstract][Full Text] [Related]
7. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
Heo YA
Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
[TBL] [Abstract][Full Text] [Related]
8. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
[No Abstract] [Full Text] [Related]
9. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
[TBL] [Abstract][Full Text] [Related]
11. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls.
Risitano AM; Peffault de Latour R; Marano L; Frieri C
Semin Immunol; 2022 Jan; 59():101618. PubMed ID: 35764467
[TBL] [Abstract][Full Text] [Related]
12. Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
Griffin M; Kelly R; Brindel I; Maafa L; Trikha R; Muus P; Munir T; Varghese AM; Mitchell L; Nagumantry S; Gandhi S; Pike A; Kulasekararaj AG; Peffault de Latour R
Am J Hematol; 2024 May; 99(5):816-823. PubMed ID: 38348608
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
Wong RSM; Pullon HWH; Amine I; Bogdanovic A; Deschatelets P; Francois CG; Ignatova K; Issaragrisil S; Niparuck P; Numbenjapon T; Roman E; Sathar J; Xu R; Al-Adhami M; Tan L; Tse E; Grossi FV
Ann Hematol; 2022 Sep; 101(9):1971-1986. PubMed ID: 35869170
[TBL] [Abstract][Full Text] [Related]
14. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
Versino F; Fattizzo B
Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
[TBL] [Abstract][Full Text] [Related]
15. Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria.
Xu B
Clin Exp Med; 2023 Jul; 23(3):717-726. PubMed ID: 35441351
[TBL] [Abstract][Full Text] [Related]
16. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Wong RSM; Navarro-Cabrera JR; Comia NS; Goh YT; Idrobo H; Kongkabpan D; Gómez-Almaguer D; Al-Adhami M; Ajayi T; Alvarenga P; Savage J; Deschatelets P; Francois C; Grossi F; Dumagay T
Blood Adv; 2023 Jun; 7(11):2468-2478. PubMed ID: 36848639
[TBL] [Abstract][Full Text] [Related]
17. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Brodsky RA; Peffault de Latour R; Rottinghaus ST; Röth A; Risitano AM; Weitz IC; Hillmen P; Maciejewski JP; Szer J; Lee JW; Kulasekararaj AG; Volles L; Damokosh AI; Ortiz S; Shafner L; Liu P; Hill A; Schrezenmeier H
Haematologica; 2021 Jan; 106(1):230-237. PubMed ID: 31949012
[TBL] [Abstract][Full Text] [Related]
18. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials.
Peixoto VP; Prudêncio C; Vieira M
Curr Med Res Opin; 2024 May; ():1-11. PubMed ID: 38727420
[TBL] [Abstract][Full Text] [Related]
19. A case report of pegcetacoplan use for a pregnant woman with paroxysmal nocturnal hemoglobinuria.
Du W; Mei L
Res Pract Thromb Haemost; 2024 May; 8(4):102435. PubMed ID: 38846741
[TBL] [Abstract][Full Text] [Related]
20. Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
Di Matteo S; Freilone R; Bruno GM; Notaro R; Moumene S; Martone N; Teruzzi C; Ciccarone A; Colombo GL
Clinicoecon Outcomes Res; 2024; 16():225-232. PubMed ID: 38623087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
